HACKENSACK MERIDIAN HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2016-01-01

Employees: -

Market Cap: -

Website: https://www.hackensackmeridianhealth.org/

Clinical Trials

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

Phase 1

Terminated

Conditions: Graft Versus Host Disease

Interventions: Drug: Cyclophosphamide and Sirolimus
Drug: Low dose IL-2 with Cytoxan + Sirolimus
Drug: Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
Drug: Low dose IL-2, Vidaza, Cytoxan & Sirolimus

First Posted Date: 2011-10-17

Last Posted Date: 2022-03-02

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 3

Registration Number: NCT01453140

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Fludarabine monophosphate, melphalan, Bortezomib

First Posted Date: 2011-10-17

Last Posted Date: 2022-05-25

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 54

Registration Number: NCT01453101

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation

Phase 3

Terminated

Conditions: Myeloid Malignancies
Acute Myelogenous Leukemia
Chronic Myelogenous Leukemia
Myeloproliferative Disorders
Myelodysplastic Syndrome

Interventions: Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)
Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)

First Posted Date: 2011-06-06

Last Posted Date: 2023-06-13

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 53

Registration Number: NCT01366612

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone

First Posted Date: 2011-02-17

Last Posted Date: 2024-12-16

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 17

Registration Number: NCT01297764

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma
Auto Stem Cell Transplant

Interventions: Drug: Bortezomib

First Posted Date: 2010-11-16

Last Posted Date: 2023-08-22

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 146

Registration Number: NCT01241708

Locations: 🇺🇸
John Theurer Cancer Center @ Hackensack University Medical Center, Hackensack, New Jersey, United States

Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL

Phase 1

Completed

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Revlimid

First Posted Date: 2010-11-16

Last Posted Date: 2023-09-14

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 18

Registration Number: NCT01241734

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Thalidomide+Melphalan +Bortezomib+stem cell transplant

First Posted Date: 2010-11-16

Last Posted Date: 2023-01-03

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 29

Registration Number: NCT01242267

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL

Phase 2

Terminated

Conditions: Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia(CLL)

Interventions: Drug: Revlimid
Drug: Azacitidine

First Posted Date: 2010-11-16

Last Posted Date: 2022-07-20

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 5

Registration Number: NCT01241786

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib 1.6 mg/m2
Drug: Bortezomib 1 mg/m2
Drug: Bortezomib 1.3 mg/m2
Drug: Melphalan

First Posted Date: 2008-11-04

Last Posted Date: 2022-08-11

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 32

Registration Number: NCT00784823

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

PET-CT Scans in Healthy Volunteers After Flu Vaccination

Not Applicable

Terminated

Conditions: Flu

Interventions: Biological: FluShield
Biological: FluShield - opposite arm
Biological: FluShield - same arm
Procedure: Blood Draws
Procedure: FDG PET-CT Scan
Genetic: Cytokine Profiling

First Posted Date: 2008-10-08

Last Posted Date: 2020-10-19

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 18

Registration Number: NCT00769002

Locations: 🇺🇸
Hackensack Univarsity medical Center, Hackensack, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy